Nightstar was acquired by Biogen for $877 million in June 2019, and delivered a 4.5x return on Syncona's original investment of £56.4 million.

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercialising novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Nightstar was one of Syncona’s first gene therapy companies, find out more about our leading gene therapy portfolio.

Download timeline PDF

Patient case study

Company details

CEO:

David Fellows

Founder:

Robert MacLaren

Syncona Representatives:

Chris Hollowood

Robert MacLaren

Founding Academic, Oxford University

“Working with Syncona has provided a partner capable of accelerating our research into becoming approved treatments for patients. I was impressed with Syncona’s plan and drive to build a company to develop multiple therapeutics for people suffering from debilitating retinal diseases.”

Emma Salisbury

Mother of a Choroideremia patient

“To then have a company like Nightstar created and the rest of the trails funded, that was huge security for us that this was going to continue. You never know because things might stop or funding might run out.”

Proof-of-concept clinical programmes for blinding conditions for which there is no treatment

2

Multiple of original cost

4.5x

IRR

72%

Sale price to Biogen

$877m

View other previous portfolio companies